Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori.
Alessandra RaimondiPierangela SepeMelanie ClapsMarco MaccauroGianluca AlibertiFilippo PaganiGiulia ApollonioGiovanni RandonGiorgia PeverelliEttore SeregniElena VerzoniGiuseppe ProcopioPublished in: Tumori (2020)
Our study provides clinically useful real-world data on radium-223, highlighting the importance of multidisciplinary patient management to guarantee the best continuum of care for patients with mCRPC.